Eli Lilly and Company is acquiring biotech firm AtaiBeckley for an up-front payment of $2.8 billion to integrate the psychedelic drug candidate BPL-003 into its neuroscience portfolio. According to company terms, Lilly will pay $6.75 per outstanding share, with potential milestone payments reaching an additional $1 billion ($2.50 per share), according to the deal terms.
Eli Lilly’s Shift Toward Psychedelic Therapeutics
The acquisition centers on BPL-003, also known as mebufotenin benzoate. This drug is a synthetic version of 5-MeO-DMT, a substance naturally produced by the Colorado River toad. U.S. regulators have already granted BPL-003 a breakthrough therapy designation, and the drug has entered Phase 3 clinical trials to treat resistant depression.
This move signals a broader industry pivot. Michael Yee, an analyst at UBS, reports that major pharmaceutical companies are increasingly investing in psychedelics to address intractable mental health conditions. This trend is further supported by the Donald J. Trump administration’s efforts to accelerate research in this field.
Did you know? BPL-003 is derived from 5-MeO-DMT, a powerful psychedelic compound found in the skin of the Incilius alvarius (Colorado River toad).
Comparing BPL-003 and Spravato
The market for treatment-resistant depression is already occupied by established players, but BPL-003 offers a different administrative profile. According to UBS analyst Michael Yee, BPL-003 may only require four to six doses or visits per year.
In contrast, Johnson & Johnson’s Spravato—which is based on ketamine—may require more than 50 visits. Yee notes that because the two drugs rely on different mechanisms of action, they represent distinct approaches to psychiatric care. Spravato is already a commercial success, with projected sales of approximately $2.5 billion this year.
| Feature | BPL-003 (AtaiBeckley) | Spravato (J&J) |
|---|---|---|
| Active Compound | 5-MeO-DMT (Synthetic) | Ketamine |
| Annual Frequency | 4 to 6 visits | 50+ visits |
| Current Status | Phase 3 Trials | Commercialized |
Funding the Biotech Buying Spree
Lilly’s ability to absorb AtaiBeckley is fueled by the massive revenue from its GLP-1 weight-loss and diabetes drugs, such as Zepbound. Last year, these blockbuster treatments accounted for roughly half of Lilly’s $65.2 billion in total revenue.
This capital has triggered an aggressive acquisition strategy. So far this year, Lilly has purchased 11 firms. Notable deals include:
- Centessa Pharmaceuticals: $6.3 billion (narcolepsy drug focus).
- Vaccine Companies: $3.8 billion total across three firms.
- Ventyx Biosciences: $1.2 billion (inflammatory diseases).
Other competitors are following suit. AbbVie recently acquired Gilgamesh Pharma, another psychedelics-focused firm, for up to $1.2 billion.
Frequently Asked Questions
What is BPL-003?
BPL-003 is a synthetic form of 5-MeO-DMT, a psychedelic substance used as a potential treatment for resistant depression.
How much is Eli Lilly paying for AtaiBeckley?
Lilly is paying $6.75 per share for an up-front total of $2.8 billion, with potential milestone payments adding up to $1 billion more.
Why is Eli Lilly buying so many biotech companies?
High revenues from GLP-1 drugs like Zepbound have provided the capital necessary to expand its portfolio into neuroscience, vaccines, and inflammatory diseases.
Want to stay updated on the evolution of neuroscience and biotech acquisitions? Subscribe to our industry newsletter or leave a comment below to share your thoughts on the future of psychedelic medicine.
Related reading